| gen: 2026/08/02:23:36 in 2 min 17.4 sec (old)bias: 4 (Center-Left) |
| type: lolsquality: 78 |
| pts: 0 |

| author: | Unknown | institution: | ProPublica | Âżporque no los dos? | |
| tl;dr | The image appears to be a ProPublica investigative-style article page focused on a Texas âspecial sessionâ and education policy, with emphasis on political maneuvering and the consequences for public schooling. The layout and accompanying photo suggest reporting on lawmakers, power brokers, and policy outcomes (likely a contested education initiative) rather than a straight breaking-news brief. The text is too small in this screenshot to reliably extract precise claims, names, or figures without risk of misquoting. | ||||
| deeper: | The article presentation and outlet indicate accountability journalism: it appears to scrutinize government actions, highlight impacts on public institutions, and foreground power dynamicsâan approach that can create a mild-to-moderate leaning toward reform/oversight framing. ProPublica generally uses document-heavy, narrative investigations and emphasizes public-interest harms, which supports a strong quality score. However, this specific screenshot is not legible enough to verify the exact sourcing, counterarguments, or key details, so the quality score is tempered. | ||||
media: | |||||
| gen: 2026/07/28:14:18 in 4 min 54.9 sec (old)bias: 3 (Center-Left) |
| type: lolsquality: 82 |
| pts: 0 |

| author: | Unknown | institution: | ProPublica | Âżporque no los dos? | |
| tl;dr | The image appears to be a ProPublica long-form investigative article page (headline, byline area, multiple long text sections, and at least one in-article photo). Due to the screenshotâs very low resolution, the exact headline, named subjects, and specific claims are not reliably legible; I canât accurately summarize the articleâs factual allegations without risking invention. Structurally, it reads like an investigative exposĂŠ: narrative lede, extensive reporting blocks, and supporting imagery. | ||||
| deeper: | Bias: The presentation looks like accountability/investigative reporting aimed at scrutinizing institutions or powerful actors, which typically reflects a mild values tilt toward transparency and reform; however, I canât verify balance (e.g., right-of-reply) from this unreadable screenshot. Quality: The layout suggests substantial original reporting (length, structure, documentary tone, photos), which generally correlates with higher rigorâbut the image resolution prevents checking sourcing, data, and whether opposing perspectives are fairly represented. | ||||
media: | |||||
| gen: 2026/07/28:04:49 in 47.1 sec (old)bias: 3 (Center) |
| type: newsquality: 82 |
| pts: 0 |

| gen: 2026/07/22:15:44 in 3 min 42.9 sec (old)bias: 4 (Center-Left) |
| type: lolsquality: 82 |
| pts: 0 |

| author: | Unknown | institution: | ProPublica | Âżporque no los dos? | |
| tl;dr | This is a ProPublica long-form investigative piece in the Education section. From the visible headline and layout, it focuses on how an organized network (likely funders/advocacy groups/operatives) is influencing education-related decision-makingâdescribing the actors involved, the methods they use (coordination, funding channels, messaging and organizing), and the downstream effects on schools and governance. The story appears to rely on document-based reporting, narrative examples, and contextual explanation rather than a short âhe-said/she-saidâ format. | ||||
| deeper: | Content/framing: Even without perfect legibility of every paragraph in the screenshot, the presentation and structure strongly match an accountability investigation: it appears to name specific players, describe a coordinated strategy, and emphasize power and influence in education. That approach tends to be critical of the subjects being investigated, which can introduce framing biasâespecially if language implies intent (e.g., ânetwork,â âhelping,â âhijack/reshape,â etc.) rather than sticking strictly to verifiable actions. Evidence signals: The article is long, structured with sections, and includes at least one chart/graphic and what looks like multiple attributed passagesâtypical markers of reporting that uses records, data, and interviews. That generally supports a higher quality score. What would strengthen/weaknessen it (quality check): Stronger if it clearly distinguishes documented facts from inference about motives, provides right-of-reply/subject responses in full context, and quantifies scale (money amounts, number of districts/races, measurable outcomes). Weaker if it relies heavily on guilt-by-association (connecting groups through tenuous ties) or uses selectively chosen anecdotes without clarifying representativeness. Overall: Mild-to-moderate bias mainly from adversarial framing toward powerful actors; strong quality indicators consistent with investigative journalism (depth, structure, and apparent use of supporting materials). | ||||
media: | |||||
| gen: 2026/07/18:02:20 in 1 min 9.8 sec (old)bias: 4 (Center-Left) |
| type: newsquality: 85 |
| pts: 0 |

| author: | Unknown | institution: | The Bureau of Investigative Journalism | Âżporque no los dos? | |
| tl;dr | Investigative report on a legal fight in Austria over whether the net price (after confidential rebates) of Merckâs blockbuster cancer drug Keytruda must be disclosed. After information requests by journalists, a lower authority moved toward release; Merck has now taken the case to Austriaâs Constitutional Court to stop publication, arguing tradeâsecret protection and harm to competition. Transparency advocates and journalists argue secrecy obscures public spending and weakens negotiating power. The case could set an EUârelevant precedent for price transparency of highâcost medicines. | ||||
| deeper: | The article is rigorous and specific: it names the court venue, describes the legal pathway, explains what information is sought (net price/discounts for Keytruda), and places the case in the broader debate over drugâprice transparency. It cites positions from both sidesâMerckâs tradeâsecret argument and journalistsâ/public interest transparency claimsâand connects the stakes to healthâsystem budgets and precedent value. Tone and framing clearly favor transparency and skepticism of pharma secrecy, which introduces a modest proâdisclosure bias, but the piece avoids emotive language and sticks largely to verifiable facts and legal context. Potential gaps: limited exploration of how confidentiality can sometimes secure lower public prices, and few independent legal experts quoted to assess the likelihood of Merckâs claims. Overall, solid investigative quality with minor slant toward transparency advocacy. | ||||
media: | |||||